Recce Pharmaceuticals Ltd Total Liabilities
Recce Pharmaceuticals Ltd total liabilities. Based on the latest financial reports, Recce Pharmaceuticals Ltd (RCE) has total liabilities worth AU$25.25 Million AUD (≈ $17.87 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Recce Pharmaceuticals Ltd (RCE) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Recce Pharmaceuticals Ltd (2013–2026)
Total liabilities of Recce Pharmaceuticals Ltd from 2013 to 2026. This chart illustrates how Recce Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data.
Recce Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Recce Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Soosan Heavy I
KO:017550
|
Korea | ₩87.41 Billion |
|
AFC Gamma Inc
NASDAQ:AFCG
|
USA | $212.45 Million |
|
NWF GROUP PLC LS-25
F:NYY
|
Germany | €182.60 Million |
|
Ahn-Gook Pharmaceutical Co. Ltd
KQ:001540
|
Korea | ₩136.13 Billion |
|
IBU tec advanced materials AG
XETRA:IBU
|
Germany | €16.58 Million |
|
Real Estate & E-Commerce Split Corp
TO:RS
|
Canada | CA$117.81 Million |
|
Kukdong Oil &
KO:014530
|
Korea | ₩271.00 Billion |
|
Tasco Bhd
KLSE:5140
|
Malaysia | RM964.62 Million |
Liability Composition Analysis (2013–2026)
This chart breaks down Recce Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Recce Pharmaceuticals Ltd's balance sheet.
Liquidity & Leverage Metrics
Recce Pharmaceuticals Ltd Total Liabilities Ratios Explained
Recce Pharmaceuticals Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Recce Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Recce Pharmaceuticals Ltd (2013–2026)
The table below shows the annual total liabilities of Recce Pharmaceuticals Ltd from 2013 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | AU$25.25 Million ≈ $17.87 Million |
+63.26% |
| 2025-06-30 | AU$15.47 Million ≈ $10.94 Million |
-2.69% |
| 2024-06-30 | AU$15.89 Million ≈ $11.25 Million |
+208.93% |
| 2023-06-30 | AU$5.14 Million ≈ $3.64 Million |
+100.79% |
| 2022-06-30 | AU$2.56 Million ≈ $1.81 Million |
+117.54% |
| 2021-06-30 | AU$1.18 Million ≈ $833.38K |
+26.44% |
| 2020-06-30 | AU$931.53K ≈ $659.11K |
-29.84% |
| 2019-06-30 | AU$1.33 Million ≈ $939.49K |
+195.84% |
| 2018-06-30 | AU$448.82K ≈ $317.57K |
-48.67% |
| 2017-06-30 | AU$874.44K ≈ $618.72K |
+322.85% |
| 2016-06-30 | AU$206.80K ≈ $146.32K |
-24.10% |
| 2015-06-30 | AU$272.47K ≈ $192.79K |
+33.69% |
| 2014-06-30 | AU$203.81K ≈ $144.21K |
+31.86% |
| 2013-06-30 | AU$154.57K ≈ $109.37K |
-- |
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary… Read more